Study Shows Prolaris Could Save Healthcare System $6B Over 10 Yrs.
December 02, 2014 at 07:03 AM EST
Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that clinical data from three studies with Prolaris in prostate cancer patients ...